Tools

LEADER 03254cam 2200553 i 4500

001 on1349358374;

003 OCoLC;

005 20230124155925.0;

006 m o d f ;

007 cr |||||||||||;

008 221031s2022 dcua ob f000 0 eng c;

024 8 a| 45-576q| (GPO jacket number);

035 a| (Sirsi) o1349358374;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:117-7;

088 a| Serial no. 117-7 (United States. Congress. House. Committee on Energy and Commerce);

245 10 a| Pathway to protection :b| expanding availability of COVID-19 vaccines : virtual hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, February 23, 2021.;

246 30 a| Expanding availability of COVID-19 vaccines;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2022.;

300 a| 1 online resource (v, 133 pages) :b| color illustrations;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| Access ID (govinfo): CHRG-117hhrg45576.;

500 a| "Serial no. 117-7.";

500 a| GPO Cataloging Record Distribution Program (CRDP).;

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: John Young, Chief Business Officer, Pfizer; Stephen Hoge, M.D., President, Moderna, Inc; Richard Nettles, M.D., Vice President of U.S. Medical Affairs, Janssen Infectious Diseases and Vaccines, Johnson & Johnson; Ruud Dobber, Ph.D., Executive Vice President, BioPharmaceuticals Business Unit, and President, North America, AstraZeneca; John Trizzino, Executive Vice President, Chief Commercial Officer, and Chief Business Officer, Novavax.;

518 a| Date of hearing: 2021-02-23.;

588 a| Description based on online resource; title from PDF title page (GovInfo, viewed Oct. 29, 2022).;

650 0 a| COVID-19 vaccinesz| United States.=| ^A1439797;

650 0 a| Vaccinesx| Developmentz| United States.=| ^A140104;

650 0 a| Vaccinesx| Standardsz| United States.=| ^A140104;

650 0 a| COVID-19 (Disease)x| Vaccinationz| United States.=| ^A1407776;

650 0 a| COVID-19 (Disease)z| United Statesx| Prevention.=| ^A1407776;

650 0 a| Coronavirus infectionsz| United Statesx| Prevention.=| ^A828712;

655 7 a| Legislative hearings.2| lcgft0| https://id.loc.gov/authorities/genreForms/gf2013025047;

776 08 i| Print version:a| United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.t| Pathway to protectionw| (OCoLC)1349358310;

856 40 u| https://purl.fdlp.gov/GPO/gpo1882157| 0;

922 a| BIBCONEWb| 20221031;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 5931904;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5931904-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 11/15/2022x| EDOCUMENTz| JERESOURCE;

Pathway to protection : expanding availability of COVID-19 vaccines : virtual hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, February 23, 2021.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2022.
Description	1 online resource (v, 133 pages) : color illustrations
Supplemental Content	https://purl.fdlp.gov/GPO/gpo188215
Subjects	COVID-19 vaccines--United States. Vaccines--Development. --United States. Vaccines--Standards. --United States. COVID-19 (Disease)--Vaccination. --United States. COVID-19 (Disease)--United States. --Prevention. Coronavirus infections--United States. --Prevention.

Portion of title	Expanding availability of COVID-19 vaccines
General note	Access ID (govinfo): CHRG-117hhrg45576.
General note	"Serial no. 117-7."
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: John Young, Chief Business Officer, Pfizer; Stephen Hoge, M.D., President, Moderna, Inc; Richard Nettles, M.D., Vice President of U.S. Medical Affairs, Janssen Infectious Diseases and Vaccines, Johnson & Johnson; Ruud Dobber, Ph.D., Executive Vice President, BioPharmaceuticals Business Unit, and President, North America, AstraZeneca; John Trizzino, Executive Vice President, Chief Commercial Officer, and Chief Business Officer, Novavax.
Date/time/place of a event note	Date of hearing: 2021-02-23.
Source of description	Description based on online resource; title from PDF title page (GovInfo, viewed Oct. 29, 2022).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Pathway to protection
Genre/form	Legislative hearings.
Standard identifier#	45-576 (GPO jacket number)
Technical rpt number	Serial no. 117-7 (United States. Congress. House. Committee on Energy and Commerce)
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:117-7

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Pathway to protection : expanding availability of COVID-19 vaccines : virtual hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, February 23, 2021.

Click here for more information about this title

Availability